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Introduction
Clostridium difficile infection (CDI) is a major cause 
of nosocomial diarrhoea and constitutes 20–30% of 
all incidents with antibiotic-associated diarrhoea.1 
CDI incidence is increasing, and the disease poses 
a serious public health challenge.2 It is associated 
with a high mortality rate, prolonged length of hos-
pitalization, and risk of readmission.3–5 Risk factors 
for developing CDI include high age, comorbidity, 
and recent antibiotic use.4 Recurrence of CDI fur-
ther increases mortality rates and rates of readmis-
sion and is a major determinant of hospital costs.6,7 
The recurrence rate following treatment of an ini-
tial CDI is 20–40%.8,9 In patients with multiple 
recurrences, the risk of another recurrence 
approaches 75%.10,11
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Abstract
Background: Recurrent Clostridium difficile infection (rCDI) is becoming increasingly common. 
Faecal microbiota transplantation (FMT) is effective for rCDI, but the costs of an FMT and 
hospital cost savings related to FMT are unknown. The aim of this study was to calculate the 
cost of an FMT and the total hospital costs before and after FMT.
Methods: This was an observational single-centre study, carried out in a public teaching 
hospital. We included all patients referred for rCDI from January 2014 through December 
2015 and documented costs related to donor screening, laboratory processing, and clinical 
FMT application. We calculated patient-related hospital costs 1 year before FMT (pre-FMT) 
and 1 year after FMT (post-FMT). Sensitivity analyses were applied to assess the robustness of 
the results.
Results: We included 50 consecutive adult patients who had a verified diagnosis of rCDI and 
were referred for FMT. The average cost of an outpatient FMT procedure if donor faeces were 
applied by colonoscopy was €3,326 per patient and €2,864 if donor faeces were applied using 
a nasojejunal tube. The total annual pre-FMT hospital costs per patient were €56,415 (95% 
confidence interval (CI) 41,133–71,697), and these costs dropped by 42% to €32,816 (22,618–
42,014) post-FMT (p = 0.004). The main cost driver was hospital admissions. Sensitivity 
analyses demonstrated cost reductions in all scenarios.
Conclusions: In a public hospital with an implemented FMT service, the average cost of FMT 
applied by either colonoscopy or nasojejunal tube was €3,095. Total hospital costs dropped by 
42% the first year after FMT. The reduction was mainly caused by reductions in the number of 
hospital admissions and in length of stay.
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The healthcare resource use and financial burden 
attributable to CDI are significant.3,12,13 Patients 
who present with CDI have longer inpatient stays, 
are more often admitted to an intensive care unit 
(ICU) and have high readmission rates. Indirect 
costs and productivity losses caused by illness-
related disability or death from CDI must be 
added to the economic burden of CDI. Particular 
challenges apply to patients with recurrent CDI 
(rCDI). A micro-costing analysis carried out in 
the United Kingdom found that the mean annual 
total costs per patient for CDI and rCDI were 
£12,710 [95% confidence interval (CI) £9,652–
15,769] and £31,121 (95% CI £19,792–42,447), 
respectively.14 Most excess costs were driven by 
additional length of hospital stay.
Antibiotics are the first treatment of choice for 
CDI. Metronidazole and vancomycin are supe-
rior to placebo in CDI, and present clinical guide-
lines recommend vancomycin as first-line 
treatment for CDI.15,16 In rCDI, second-line 
treatments such as tapered vancomycin, fidax-
omicin and adjuvant rifaximin may be used.9 
Repeated courses of antibiotic treatment may 
have detrimental effects on the intestinal micro-
biota,17,18 and therapies that ensure sustained 
remission and recovery of the intestinal microbi-
ota are warranted.
Faecal microbiota transplantation (FMT) is an 
emerging therapeutic option for rCDI and is supe-
rior to both high-dose10 and tapered11 vancomycin 
as well as autologous FMT.19 Resolution rates of 
70–90% following FMT for rCDI have been con-
sistently reported in both observational studies20–24 
and randomized trials.10,11,19,25,26 FMT may pro-
vide sustained symptom resolution and general 
well-being,27 and it may also be effective in treating 
complicated or severe CDI.28,29 Accordingly, clini-
cal FMT frameworks have evolved across Europe, 
Australia, Asia and the USA30–36 to safely provide 
FMT for patients with rCDI. The costs related to 
operating these clinical services and their derived 
cost savings are unknown. A number of health eco-
nomic evaluations have been published, all indi-
cating that FMT is cost-effective.37–39 All these 
studies were model-based incremental analyses 
where only relevant costs, that is, costs that differ 
between the alternatives, were included. They did 
not provide an accurate measure of the total mean 
cost of FMT. Most studies were carried out in 
countries with a fully or partly privately funded 
healthcare system. Furthermore, modelling studies 
that present evidence-based care pathways tend to 
underestimate real-world cost because waste and 
most types of adverse events are assumed to be 
constant.40
Clinicians and healthcare decision-makers need 
ways to understand and measure their costs over 
the full course of treating the patient’s medical 
condition, with a way to increase the value to 
patients with similar or reduced costs.41 
Calculated costs may differ from estimated 
costs, and costs depend on the national and 
regional healthcare systems. Cost analyses based 
on detailed real-world data are needed to accu-
rately guide decision-making and the dissemina-
tion of FMT.37–39,42–44
In this study, we calculated the direct cost of an 
FMT in a public, hospital-based, European gas-
troenterology centre with an established clinical 
FMT service that was affiliated with a public 
blood centre. We further calculated the one-year 
cost savings following treatment with FMT to a 
consecutive cohort of patients with rCDI.
Methods
Study design
This was an observational, cohort-based cost 
analysis carried out in a public Danish referral 
centre for gastroenterology. We included all adult 
patients with rCDI who were referred for FMT 
from 1 January 2014 to 31 December 2015. 
Disease recurrence was defined as recurrence of 
diarrhoea with positive Clostridium difficile toxin 
test less than 8 weeks following treatment with 
vancomycin or fidaxomicin and initial symptom 
resolution with this treatment. In Denmark, 
access to healthcare services is public and free of 
charge. Funding is tax based, and the access to 
treatments is decided by the National Board of 
Health. In this study, experimental treatments 
were funded by a grant donation from the Danish 
Regions, aiming to investigate the potential to 
rationalize or prevent antibiotic treatments.
To obtain an accurate measure of the FMT costs 
and the hospital cost savings during the complete 
cycle of hospital care, we applied a time-driven 
activity-based costing approach (TDABC).45 
TDABC is a bottom-up approach that uses pro-
cess mapping to identify all types of costs and all 
personnel used in the complete cycle of care. The 
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method is suggested for healthcare research as a 
cost approach that provides more accurate esti-
mates of healthcare costs than traditional full-cost 
allocation methods. The cost analysis involves the 
following distinct phases: (1) process mapping, 
(2) identification of types of resources, (3) meas-
uring the amount of resources used, (4) valuation 
of individual resource items, (5) estimation of 
total and average costs per patient and (6) sensi-
tivity analyses.41,45–47
Calculation of FMT cost
The economic perspective used for estimating 
costs of FMT was that of a publicly funded hospi-
tal, including the blood bank collection centre. In 
Denmark, donors are voluntary and unpaid local 
citizens, and donors’ private cost of transport and 
time was not reimbursed and, thus, not included. 
The clinical FMT framework within this study is 
described elsewhere.34 In brief, the clinical frame-
work is separated into three main activities that 
map all aspects related to FMT: (1) donor recruit-
ment and screening, (2) laboratory processing 
and (3) clinical application (Figure 1). Cost cal-
culations were performed separately for the three 
main activities. All costs were adjusted to the 
price level in year 2015.
Cost of donor recruitment and screening. The cost 
calculation was based on a stepwise screening 
algorithm that was applied in a cohort of healthy, 
Danish blood donors.48 Among 155 healthy blood 
donors who were asked to become faeces donors, 
31 (20%) eventually passed all screening tests. 
Among 137 (88%) who consented to participate, 
79 (58%) were excluded following completion of 
an electronic prescreening questionnaire. Among 
the remaining 58, 15 (26%) failed the blood and 
faecal screening, and 12 (21%) had an incom-
plete screening. Among the 31 blood donors who 
eventually qualified as faeces donors, 8 delivered 
donor faeces for patient treatment in the present 
study. Faeces donation was scheduled in donation 
rounds, which each consisted of faeces from five 
defaecations from the same donor and delivered 
during 1–3 weeks. At each donation, documenta-
tion of donor health and traceability of the donor 
faeces was documented. A negative predonation 
screening was valid up to 6 months before initia-
tion of a donation round. After each donation 
round, all blood and faecal screening tests were 
repeated using repeat blood samples and the 
donated faeces, before release of the donor mate-
rial for patient treatment.
Measurements of the personnel’s time used to 
conduct donor interviews, screening procedures 
and documentation as well as all unit costs 
including overhead costs for the screening proce-
dures were provided by the Department of 
Biochemistry at Aarhus University Hospital 
(AUH), Denmark, the National Serum Institute 
(www.ssi.dk), Copenhagen, Denmark and the 
Department of Clinical Microbiology, Hvidovre 
Hospital, Denmark.
Figure 1. Clinical application framework for faecal microbiota transplantation (FMT), including donor 
recruitment and screening, laboratory processing and clinical application (adapted from Jørgensen et al.34).
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Cost of laboratory processing. Data for actual pur-
chase prices of equipment excluding taxes and of 
disposables and wage levels (gross salaries) for all 
personnel groups were provided by the local 
accounting department (Table 1). Time measure-
ments were provided by the Department of Hepa-
tology and Gastroenterology and the Department 
of Biochemistry, AUH. The costs for laboratory 
processing were used to calculate the average cost 
per 50 g of donor faeces. Overhead costs, including 
facilities, equipment and other indirect costs, were 
estimated in cooperation with the Accounting 
Department, AUH.
Cost of clinical application. Costs of the compo-
nents related to the clinical application of FMT, 
that is, patient assessment, diagnostic tests, antibi-
otics, transplantation, monitoring and follow-up 
were obtained from the patients’ electronic patient 
records (EPRs) as a quality improvement study 
conducted within the Department of Hepatology 
and Gastroenterology, AUH. Two separate cost cal-
culations were performed, depending on whether 
colonoscopy or nasojejunal (NJ) tube was used for 
application. Costs for both procedures were calcu-
lated using reimbursement tariffs from the Danish 
Ambulant Grouping System (DAGS), 2015, for an 
Table 1. Applied unit costs (in euros) of healthcare resources and quantity over 2 years in 50 patients treated 
with faecal microbiota transplantation (FMT).
Healthcare resource use, cost components Quantity in 50 patients 
treated with 68 procedures
Applied unit costs (€)
Donor recruitment and screening  
 Study nurse per hour 12 33
 Blood and faeces screening 24 2,102
Laboratory processing  
 Laboratory technician per hour 189 43
 Laboratory equipment 68 29
 Laboratory facilities 68 75
Clinical application  
 Colonoscopy (uncomplicated) 34 811
 Nasojejunal tube with X-ray control 34 349
 Vancomycin 125 mg QID for average 6 days 68 163
Contacts with the hospital  
 Hospital bed day 2,971 1,108
 Days in intensive care unit 114 4,421
 Outpatient visit 1,162 208
 Contact with emergency room 83 208
 Telephone consultation 930 20
Days with antibiotic treatments for Clostridium 
difficile
 
 Metronidazole (1,500 mg per day) 1,354 1
 Vancomycin (500 mg per day) 5,407 27
 Fidaxomicin (400 mg per day) 363 213
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outpatient visit with patient history and two follow-
up contacts by telephone. DAGS rates are deter-
mined at the national level and are provided each 
year from the Ministry of Health. The rates cover all 
hospital costs except research, depreciation and 
capital costs. Tariffs are calculated from the princi-
ples of activity-based costing (without profit) based 
on publicly available accounting information from 
all Danish public hospitals. The cost per colono-
scopically administered FMT further included a 
DAGS rate for an uncomplicated colonoscopy, and 
the cost of application by NJ tube included the 
DAGS rate for an uncomplicated abdominal X-ray. 
The price for the NJ tube (Flocare Bengmark, 
Nutricia, Utrecht, Netherlands) was provided by 
AUH and was included in the total costs for the NJ 
tube procedure.
Six (12%) of the patients each required 1 day of 
admission for preparation for the FMT procedure 
and monitoring. A rate for hospital admission was 
calculated using an average reimbursement tariff 
for the Department of Hepatology and Gastroen- 
terology, AUH. None of the included patients 
experienced complications following FMT. 
Therefore, no costs from hospital admissions for 
complications contributed to FMT costs. Expenses 
related to research and development were not 
included in the FMT cost calculation.
Calculation of hospital costs and savings
Patient EPRs were reviewed to document the 
number and length of hospital admissions, 
admissions to an ICU, antibiotic use, outpatient 
visits, emergency room visits and telephone con-
sultations 1 year before the index FMT (pre-
FMT) and 1 year following the index FMT 
(post-FMT). The index FMT was defined as the 
first FMT for each patient and separated the pre-
FMT year from the post-FMT year (Figure 2).
Hospital costs. The applied average unit costs of 
hospital admission and intensive care admission 
were €1,108 and €4,421, respectively, using the 
DAGS tariff in 2014 for the Department of Hepa-
tology and Gastroenterology, AUH. To calculate the 
costs of outpatient visits and telephone consulta-
tions, DAGS rates for an outpatient visit with patient 
history and a telephone consultation were applied. 
These rates were €208 and €20, respectively. The 
costs of contacts with the emergency room were 
assumed to be the same as outpatient visits. Prices 
for antibiotic treatments with metronidazole, vanco-
mycin, or fidaxomicin were obtained from the Dan-
ish Medicines Agency and were €1, €27 and 
€213 per day, respectively (www.medicinpriser.dk). 
All unit costs were adjusted to the price level in 
2015. All applied unit costs are listed in Table 1.
Sensitivity analyses
When data are collected and assumptions are 
made to estimate costs, uncertainty arises as to the 
accuracy of the estimates and the emphasis that 
can be placed on the results. The impact of this 
uncertainty can be assessed by undertaking a num-
ber of sensitivity analyses. In the present study, the 
Figure 2. Study design with calculation of total hospital-related costs 1 year before the first faecal microbiota 
transplantation (FMT) (pre-FMT) and 1 year after the first FMT (post-FMT). Cost drivers included hospital 
admission days, intensive care unit admission days, antibiotics use, outpatient visits, telephone consultations, 
and costs related to the FMT procedure. All costs related to FMT procedures were included in the post-FMT year.
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risk of bias related to the study design and patient 
selection is of particular interest. As a supplement 
to confidence intervals for costs and statistical test-
ing, we therefore conducted a number of scenario 
analyses. This is a particular form of multi-way 
sensitivity analysis where the expected outcomes 
are estimated under an alternative, but realistic set 
of assumptions. In each sensitivity analysis, abso-
lute and relative differences between the base case 
and the specific scenario were calculated. All costs 
in the sensitivity analyses were calculated as aver-
age costs per patient.
First, comorbidity preceding the index CDI may 
have contributed to pre-FMT costs, particularly 
in patients who had their FMT performed less 
than 1 year after their index CDI. In the scenario 
analysis, only days of admission and days in ICU 
that occurred after the index CDI were included 
in the pre-FMT cost calculation. The post-FMT 
time period was truncated to the same number of 
days on a patient-to-patient basis.
Second, patients who died during follow-up did 
not contribute to post-FMT costs to the same 
degree as patients with complete follow-up. In the 
second analysis, we excluded patients who died 
during follow-up.
Third, a few patients with an extraordinarily high 
number of hospital admission days may have 
driven up hospital costs. We therefore excluded 
the 5 (10%) patients with the highest pre-FMT 
hospital costs in the third analysis.
Fourth, patients in intensive care may have driven 
up costs for both ICU treatment and overall hos-
pital costs. In the fourth analysis, all patients with 
ICU admission during the study period were 
excluded.
Statistical analyses
All patient and cost data were documented in a 
central database using Research Data Capture 
software (REDCap, www.redcap.au.dk). Data 
obtained from EPRs were entered in REDCap 
4.4.17 and exported and analysed using the 
Statistical Package for the Social Sciences 
(SPSS Corp., IBM Analytics, NY, USA) version 
23. Mean and 95% CIs were determined for all 
hospital costs. In situations where cost variation 
could not be calculated, the uncertainty in mean 
costs was estimated using an expert opinion and 
applying a conservative estimate of ±20%. 
Median, interquartile range (IQR) and total range 
were reported for the baseline characteristics of 
the study population. A paired t-test was used to 
test for statistically significant differences between 
means of admission costs before and after FMT. 
A statistical significance level of 0.05 was applied 
throughout.
Ethical considerations
All procedures were performed in compliance with 
the standards outlined in the European Union 
Tissue and Cells Directives. Informed consent was 
obtained from all 50 patients and 8 faeces donors. 
Because this was a quality improvement study, the 
board of the Department of Hepatology and 
Hepatology at AUH approved the study and no 
formal Ethics Committee approval was required. 
The Danish Data Protection Agency approved 
data storage (j.no. 1-16-02-15-16).
Results
Patient characteristics
A total of 50 patients with rCDI were included in 
this study. The median age was 65 years, and 29 
(58%) were female. The patients had a median 
Charlson comorbidity score of 3 (IQR 0.3–4.8) 
and a median World Health Organization (WHO) 
performance score of 1 (0.3–3). Eleven (22%) 
patients were admitted to the ICU, 13 patients 
(26%) suffered from inflammatory bowel disease 
(IBD) and 29 (58%) were being treated with pro-
ton pump inhibitor (PPI) prior to their index 
FMT. All baseline patient characteristics are pre-
sented in Table 2.
Twenty-nine (58%) patients received their index 
FMT via colonoscopy and 21 (42%) via NJ tube. 
The median number of days from the index CDI 
to the index FMT was 259 days (IQR 80–365 days), 
and 12 (24%) patients suffered their first CDI 
more than 1 year prior to their index FMT. Four 
(8%) patients died during the year of follow up. 
No deaths were related to the FMT procedures. 
Two (4%) patients declined follow up before week 
52. Of the remaining 44 with complete 1-year fol-
low-up data, 40 (91%) had clinical resolution and 
a negative Clostridium difficile toxin test 52 weeks 
after the index FMT. Antibiotic treatment during 
follow up was provided to 29 patients, and seven 
patients underwent a colectomy owing to active 
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IBD. During the follow-up period, 18 patients 
required an additional FMT owing to CDI recur-
rence; this was delivered by colonoscopy to 5 
(28%) patients and by NJ tube to 13 (72%) 
patients.
Cost of FMT
The total cost of one FMT was calculated as the 
sum of average costs related to donor screening, 
laboratory processing, and clinical application.34 
The total calculated cost of an FMT applied by 
colonoscopy was €3,326 (95% CI 2,660–3,991) 
and €2,864 (2,291–3,437) for an FMT delivered 
through an NJ tube. The weighted average cost 
per FMT was €3,095 (2,476–3,714). Divided into 
each major activity of the FMT service, the costs 
of screening were €1,029 (823–1,235), laboratory 
processing €665 (532–798) and clinical applica-
tion €1,632 (1,306–1,958) for colonoscopy and 
€1,170 (936–1,404) for an NJ tube (Table 3).
Hospital-related costs
The total annual costs of hospital admissions, ICU 
admissions, antibiotic use, outpatient visits, emer-
gency room visits and telephone consultations per 
patient amounted to €56,415 (41,133–71,697) 
pre-FMT, and these dropped by 42% to €32,816 
(22,618–42,014) post-FMT (p = 0.004). Costs 
for hospital admissions were the main cost driver 
(Figure 3). The average calculated costs of hospital 
admissions per patient pre-FMT were €41,286, 
and this dropped to €22,649 post-FMT, a cost 
reduction of €18,638 (45%). The cost reduction 
was caused by reductions in both the number of 
admissions and the length of stay for each hospital 
admission (Figure 4). The median number of days 
of hospital admission, excluding admissions to 
ICUs, dropped from 31 days pre-FMT to 8 days 
post-FMT (p < 0.0001). Costs of admissions to 
ICUs aggregated to €9,285 per patient pre-FMT 
and €796 post-FMT, corresponding to a cost 
reduction of 91% (p = 0.04). The number of out-
patient visits, telephone consultations, antibiotic 
treatments, and visits to the emergency room 
remained largely unchanged (Figure 3).
Sensitivity analyses
We analysed the robustness of the results using 
multiway scenario analyses to characterize four 
alternative sets of assumptions for estimating costs 
of FMT and potential cost savings (Table 4). The 
results of the scenario analyses were compared to 
the base case mean total hospital costs of €56,415 per 
patient pre-FMT and €32,816 post-FMT.
Because CDI most commonly follows antibiotic 
treatment, comorbidity preceding the index CDI 
could contribute to and in part explain the high 
pre-FMT hospital costs. In the first sensitivity 
analysis, we therefore truncated the study period 
to the duration from the index CDI to the index 
FMT in order to exclude costs related to the mor-
bidity leading to the first CDI. Total costs per 
patient in this scenario were €40,820 pre-FMT, 
compared with €56,415 in the base case. Costs 
dropped by 40% to €24,441 post-FMT, docu-
menting an unchanged relative cost reduction.
Second, four patients died during the follow-up 
period and did not have complete follow-up data. 
After analysis excluding these patients, the costs 
dropped from €53,710 per patient pre-FMT to 
€32,008 per patient post-FMT, corresponding to 
a 40% reduction.
Third, if the five patients who contributed most 
to hospital costs were removed from the study, 
absolute but not relative cost reductions dropped. 
Total costs dropped from €47,010 per patient 
pre-FMT to €27,839 per patient post-FMT, that 
is, a reduction of 41%.
Table 2. Patient characteristics (n = 50) at referral 
for faecal microbiota transplantation (FMT) for 
recurrent Clostridium difficile infection (rCDI).
Patient characteristic Measure
Age (years), median (IQR) 65 (48–73)
Gender, female n (%) 29 (58%)
Charlson Comorbidity Index, 
median (IQR)
3 (0.3–4.8)
WHO performance score, median 
(IQR)
1 (0.3–3)
Days from index CDI to index FMT, 
median (IQR)
129 (80–365)
Intensive care unit admission,  
n (%)
11 (22%)
Inflammatory bowel disease, n (%) 13 (26%)
Proton pump inhibitor use, n (%) 29 (58%)
IQR, interquartile range; WHO, World Health Organization.
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Table 3. Average hospital costs for a faecal microbiota transplantation (FMT). All amounts in euros.
Healthcare resource use, cost components Quantity Per FMT cost (€)
Mean
Screening facilities and equipment  
 Recruitment 40 70 (56–84)
 Outpatient visit with patient history 35 107 (86–128)
 Blood and faeces screening 24 742 (594–890)
 Information to approved donors 8 24 (19–29)
 Information to rejected donors 32 5 (4–6)
 Data management 40 81 (65–97)
Total – 1,029 (823–1,235)
Laboratory facilities and equipment  
 Processing 75 82 (66–98)
 Cryopreservation including –80°C freezer with alarm 75 160 (129–193)
 Pre-procedure preparation 75 33 (26–39)
 Waste (10% of total donations) 7 22 (17–26)
 Biobank for traceability and quarantine management 75 178 (142–214)
 Transport 75 10 (8–12)
 Infrastructure N/A 100 (80–120)
 Data management N/A 80 (64–96)
Total – 665 (532–798)
Clinical application  
 Initial outpatient visit with patient information 68 208 (167–250)
 Hospital admission for treatment 6 98 (78–118)
 Colonoscopy (uncomplicated) 34 811 (649–973)
 Nasojejunal tube with X-ray control 34 349 (279–419)
 Vancomycin 125 mg QID for average 6 days 408 days 292 (144–260)
 Two faecal tests during follow up 68 183 (146–219)
 Follow-up by telephone week 1 and week 8 after FMT 68 40 (32–48)
Total – 1,981 (1,585–2,377)
Total price per FMT  
 Total cost per FMT, colonoscopy 34 3,326 (2,660–3,991)
 Total cost per FMT, nasojejunal tube 34 2,864 (2,291–3,437)
Weighted average price of one FMT 3,095 (2,476–3,714)
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Fourth, if the patients who were admitted to 
ICUs were excluded from the study, the costs 
before FMT were €39,365, and these dropped to 
€29,927 after FMT, that is, a 24% reduction.
Taken together, the primary findings were robust 
and insensitive to exclusion of outliers or patients 
with skewed contribution to the study data.
Discussion
This cohort study is the first to provide a direct 
calculation of the costs of an FMT and the 
derived hospital cost savings following FMT in 
patients with rCDI. The average net price for 
an FMT was €3,095. Total annual hospital 
costs dropped by 42% during the first year after 
an FMT.
Figure 3. Comparison of costs 1 year before (pre-FMT) and 1 year after (post-FMT) faecal microbiota 
transplantation (FMT) for recurrent Clostridium difficile infection (rCDI), in total (A) and subdivided into hospital 
cost of hospital admission (B), intensive care unit (C), outpatient visits (D), and antibiotics (E). Costs are 
displayed in euros as the mean per patient with 95% confidence intervals (CI) as error bars.
Figure 4. The number of admissions and the length of each admission dropped from the year before (left) to 
the year after (right) faecal microbiota transplantation (FMT) for recurrent Clostridium difficile infection (rCDI).
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No previous study calculated the costs of an FMT 
based on real-world data and with separation into 
the three major activities of a clinical framework, 
that is, donor recruitment and screening, labora-
tory processing and clinical application. Costs spe-
cifically related to screening were calculated in a 
recent Canadian survey where 49 volunteers were 
screened, only to obtain one (2%) eligible donor, 
with a cost of $15,190 equivalent to €13,546 in 
2016.49 In the present study, expenses for screen-
ing 40 potential donors that yielded eight eligible 
donors who delivered faeces for 68 FMT proce-
dures were €69,972, or €8,746 per donor. A recent 
study investigated CDI subtype-guided FMT 
compared with vancomycin treatment and 
reported an FMT cost per patient of €7,614 over a 
30-day period and a 10% reduction in costs com-
pared with vancomycin, despite an isolated cost 
per FMT of €1,188.50 This price for an FMT is 
considerably lower than the price reported in the 
present study. The different FMT costs may be 
attributable to different scenarios, one of which 
related to economy of scale, because Jiang and 
coworkers had access to a universal stool bank.
Reduction of FMT costs may be an independent 
aim of a clinical FMT service, and cost reduc-
tions may be achieved through multiple strate-
gies. High donor eligibility is optimum. In our 
study, donor screening yielded 20% eligibility, 
which is high compared with 2% in Dutch36 and 
3% in Openbiome investigations.51 The number 
of donations per round before recheck may be 
increased from five used in this study, thus reduc-
ing the screening costs per donation. However, 
such an increase implies a risk of discarding more 
faecal samples if they fail post-donation tests, and 
it potentially affects the eligibility if donors feel 
that too many donations are requested.
The main driver of the cost savings in the present 
study was a 45% reduction in the total days of hospi-
tal admission following FMT. The most marked 
cost reduction was caused by the 91% reduction in 
ICU admissions, which indicates that FMT may 
also reduce the severity of illness by curing rCDI 
rather than just reducing length of stay. Organizational 
initiatives to reduce the overall occurrence of CDI 
remain pivotal, including discontinuation of offend-
ing antibiotics where possible and ensuring contact 
precautions and hand hygiene.52
Cost-effectiveness studies based on modelling 
reported high initial costs when using FMT 
instead of vancomycin. In this study, the high 
effectiveness and reduction in hospital costs more 
than make up for the extra costs of a single FMT. 
The modelling studies compared costs and effects 
of FMT with standard antibiotic treatments, 
including vancomycin, metronidazole and fidax-
omicin, and indicated a potential for substantial 
savings and improved quality of life. The reduc-
tion in cost when treating patients with FMT was 
primarily a result of reduced length of stay in the 
hospital due to a faster recovery time.38,42,44 The 
present study, using real-world data, confirmed 
this hypothesis.
The present study demonstrated a 30% decrease 
in antibiotics use post-FMT. This decrease may 
in part be caused by the general advice to avoid 
antibiotics following a CDI.16 With this in mind, 
the reduction is less pronounced than expected, 
and it is uncertain to what degree the FMT itself 
contributed.53,54 Patients’ fear of suffering 
another rCDI may have limited the decrease in 
antibiotic use.55 Indeed, we found that some 
patients had antibiotics prescribed only as a pre-
caution in the case of clinical recurrence. This 
finding contrasts with the findings of a study by 
Jalanka et  al., which advises against the use of 
antibiotics as prophylaxis or in other treatable 
aspects immediately after FMT.27 Future rand-
omized studies should investigate whether FMT 
may facilitate reduced antibiotic use.
This study has important limitations. It was a 
single-centre study, carried out in an institution 
with an established FMT service. Generalizability 
to institutions without this framework is there-
fore not straight forward, and future studies 
should describe means to disseminate FMT as a 
clinical option for all patients, thus ensuring 
geographical independence. All costs were 
standardized to 1 year before and 1 year after 
FMT. This predisposes to bias because 38 
patients suffered their index CDI less than 1 
year prior to their index FMT, and the decrease 
in hospital costs following FMT may therefore 
be explained by other factors than the FMT 
itself. Many of the included patients had marked 
comorbidities and were admitted before their 
first CDI. The high difference in costs from the 
year preceding FMT to the year after FMT 
could in part be due to their comorbidities and 
not FMT. True cost savings are seen in patients 
who suffered their index CDI more than 1 year 
before their index FMT and by truncating the 
Therapeutic Advances in Gastroenterology 12
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pre-FMT period to the days between the index 
CDI and the FMT as done in the first sensitivity 
analysis. Adjustment for increasing patient age 
during the 2-year study period was not per-
formed and would pull the results towards the 
null hypothesis. Four of the patients died within 
1 year after their index FMT and did not con-
tribute to hospital costs for a whole year. 
Sensitivity analyses demonstrated that the costs 
savings were not caused by patients dying and 
that cost savings were equal in all patient groups. 
Finally, this study included only hospital costs, 
but a societal view would have been ideal to 
clarify the saving potential of curing rCDI with 
FMT. A cost-effectiveness study of FMT for 
patients with IBD found that FMT also lead to 
savings in societal costs,13 and this may also be 
applicable to the present study.
In conclusion, the cost of an FMT was low in 
comparison with rCDI-associated hospital costs, 
which decreased by 42% the year following the 
index FMT, even when including costs of FMT 
in the analyses. Randomized controlled trials that 
compare FMT with state-of-the-art medical ther-
apies would help clarify to what degree FMT is 
the main reason for the cost savings.
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